SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001819790-22-000039
Filing Date
2022-11-09
Accepted
2022-11-08 21:50:50
Documents
14
Period of Report
2022-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K tars-20221109.htm   iXBRL 8-K 35669
2 EX-99.1 exhibit991tarsus1192022pre.htm EX-99.1 129539
6 GRAPHIC picture1.jpg GRAPHIC 5866
  Complete submission text file 0001819790-22-000039.txt   326029

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tars-20221109.xsd EX-101.SCH 1890
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tars-20221109_lab.xml EX-101.LAB 24831
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tars-20221109_pre.xml EX-101.PRE 13035
8 EXTRACTED XBRL INSTANCE DOCUMENT tars-20221109_htm.xml XML 11334
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

IRS No.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 221370484
SIC: 2836 Biological Products, (No Diagnostic Substances)